The Generic Pharmaceutical Association on Thursday launched a biosimilars division with “double-digit” membership and more-than $1 million in dedicated funding, with more companies pledging to join, outgoing GPhA CEO and President Ralph Neas told Inside Health Policy . The generic drug lobby said the new Biosimilars Council will comprise manufacturers and stakeholders involved in bringing biosimilars to market and will work to ensure a “positive” regulatory, reimbursement, political and policy environment that supports patient access. GPhA will also form a...